title: Long-term results of paclitaxel in FIGO stage III ovarian carcinoma.
abstract: The combination of platinum and paclitaxel is the standard treatment of advanced ovarian carcinoma; however, recent studies have questioned the actual role of the combination as compared to either of the two agents alone. We report an open-label, two-center, phase II study of upfront paclitaxel for patients with histological diagnosis of stage III ovarian carcinoma. Treatment consisted of paclitaxel at 175 mg/m2 administered in a 3-h infusion every 21 days. Response was evaluated after the third course by either laparoscopy or exploratory laparotomy. Patients with stable or progressive disease discontinued treatment, whereas responding patients continued treatment until a maximum of six courses. Response, toxicity, time to progression (TTP) and survival were evaluated. From November 1993 to December 1995, 30 patients were accrued. All patients underwent primary cytoreduction; 17 (57%) and 13 (43%) patients had residual tumors <2 and >2 cm, respectively. Of 27 patients evaluable, objective responses were seen in 18 (66.4%) (95% CI 49.5-83.2)--12 complete (45%) and six partial (22%). Four patients had stable disease (15%) and five (18%) patients progressed. A total of 149 courses were administered to 30 patients, median 4 (range 1-6). Grade 3/4 neutropenia was seen in 13% of courses, peripheral neuropathy, myalgia and arthralgia were frequent, but transitory and relieved with analgesics. At a median follow-up time of 44.5 months (0-99) the TTP and median survival were 16.6 and 43.1 months, respectively. We conclude that single-agent paclitaxel is an effective and well-tolerated first-line treatment for advanced ovarian carcinoma.
authors.affiliation: Instituto Nacional de Cancerología, Tlalpan, Mexico.
authors.forename: Dolores
authors.initials: D
authors.lastname: Gallardo-Rincón
authors.forename: Leonel
authors.initials: L
authors.lastname: Pérez-Landeros
authors.forename: Luis Fernando
authors.initials: LF
authors.lastname: Oñate-Ocaña
authors.forename: Alejandro
authors.initials: A
authors.lastname: Mohar
authors.forename: Germán
authors.initials: G
authors.lastname: Calderillo
authors.forename: Jaime
authors.initials: J
authors.lastname: de la Garza
authors.forename: Paula
authors.initials: P
authors.lastname: Cabrera
authors.forename: Benito
authors.initials: B
authors.lastname: Sánchez
authors.forename: Alfonso
authors.initials: A
authors.lastname: Dueñas-Gonzalez
mesh_terms: D000328:Adult; D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects / Q000627:therapeutic use*; D018450:Disease Progression; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D010053:Ovary / Q000473:pathology; D017239:Paclitaxel / Q000009:adverse effects / Q000627:therapeutic use*; D016019:Survival Analysis
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D017239:Paclitaxel